Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer

Authors

Tiffany TrainaFollow
Lee W. Jones
Victoria Blinder
Jessica Scott
Leigh Ann BoyleFollow
Artavazd ArumovFollow
Tina Alano
Sujata PatilFollow
Patricia DeFuscoFollow
Nicholas Lamparella DO, Lehigh Valley Health NetworkFollow
Mark RobsonFollow
Ayca GucalpFollow

Publication/Presentation Date

12-2019

Published In/Presented At

Traina, T., Jones, L., Blinder, V., Scott, J., Boyle, L., Arumov, A., Alano, T., Patil, S., DeFusco, P., Lamparella, N., Robson, M., & Gucalp, A. (2019, December). Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. Presentation presented at: San Antonio Breast Cancer Symposium, San Antonio, TX.

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation